MADI

AI Digital Twin Clinical Trial Platform

Revolutionizing drug development with AI digital twin technology for faster and safer clinical trials.
Traditional drug development takes an average of 15 years and costs over $2 billion, with a 90% failure rate making it a high-risk endeavor.
The significant costs and lengthy development periods in clinical trials particularly delay patients' access to new treatments.
MADI creates sophisticated digital twins using generative AI technology, solving control group recruitment challenges and reducing clinical trial duration by 20%. By minimizing the need for actual patient recruitment, we provide more patients with equitable access to treatment opportunities. We aim to grow as an AI-CRO partner for global pharmaceutical companies by optimizing our digital twin technology for Korean and Asian markets.